Haptoglobin (Hp) polymorphism has recently been demonstrated to be associated with morbidity risk and to impact significantly the protective and therapeutic effects of antioxidant vitamin E in disorders associated with increased oxidative stress, such as diabetes. This suggests that patient population selection based on disease type and Hp polymorphism may dramatically improve the protective and therapeutic effects of administered vitamin E on diseases.
